Top Markets
#1 Fake World Assets Fake World Assets +11.84%
#2 TENDIES TENDIES +6.51%
#3 Janction Janction +5.07%
#4 GoPlus Security GoPlus Security +4.45%
#5 B3 (Base) B3 (Base) +4.30%
#6 Status Status +4.24%
#7 Everything Everything +3.72%
#8 TronBank TronBank +3.26%
#9 Cross Cross +2.99%
#10 Tutorial Tutorial +2.63%
Coin of the day
Fake World Assets Fake World Assets
설정
언어
한국어
통화
USD
테마
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
주식 순위 #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
주가
$0.6379482
마지막 동기화: 2023-05-22
시가총액
$5.98M
변동 (1일)
-0.44%
변동 (1년)
0.00%
국가
FR
거래 Nicox S.A. (COX)

카테고리

Healthcare
Nicox S.A. (COX)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Nicox S.A.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Nicox S.A.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE